Endometrial preparation using gonadotropin-releasing hormone agonist prior to frozen-thawed embryo transfer in women with repeated implantation failure: An RCT.

OA: gold CC-BY-NC-4.0
AI-generated deep summary by qwen3.7-flash, 2026-08-27 · read from full text

This randomized clinical trial evaluated the efficacy of pretreating women with idiopathic repeated implantation failure using a GnRH agonist prior to frozen-thawed embryo transfer. The study enrolled 67 participants, comparing a group receiving pituitary down-regulation via GnRH agonist against a control group receiving standard hormone replacement therapy alone. Results indicated no statistically significant difference in chemical pregnancy, clinical pregnancy, or implantation rates between the two groups, although numerical trends favored the intervention arm. Relevance to endometriosis: The paper is centrally about adenomyosis and endometriosis — specifically, it cites prior research demonstrating that GnRH agonists improve outcomes in these conditions by reducing inflammation and macrophage aggregation, while also excluding patients with uterine anomalies such as myomas during enrollment.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

BackgroundPreparation of endometrial thickness in frozen-thawed embryo transfer (FET) is extremely important, particularly in repeated implantation failure (RIF) patients.ObjectiveThis study aimed to investigate the clinical outcomes of FET cycles among RIF women, based on the effects of administering gonadotropin-releasing hormone (GnRH) agonist prior to estrogen-progesterone preparation of the endometrium.Materials and methodsIn this randomized clinical trial, 67 infertile women who were candidates for FET were divided into two groups: A) case group (n = 34), treated with GnRH agonist prior to endometrial preparation and B) control group (n = 33), which received the routine protocol. (6 mg daily estradiol started from second day) The clinical outcomes) including chemical and clinical pregnancy, in addition to implantation rates, were compared between the two groups.ResultsThe results showed no significant differences in women's age (p = 0.558), duration (p = 0.540), type (p = 0.562), and cause of infertility (p = 0.699). Regarding pregnancy and implantation rates, there was a trend toward an increase in the case group; however, differences were not statistically significant.ConclusionAlthough our results showed no significant differences between groups. Because there are trends to better results in case group larger sample size may show significant difference.
Full text 10,250 characters · extracted from pmc-nxml · 2 sections · click to expand

Section

In conclusion, our study found that the use of a GnRH agonist in women with RIF may improve endometrial receptivity and increase pregnancy rate. However, differences were not statistically significant. Therefore, additional large prospective studies are necessary on this topic.

Coi Statement

The authors declare no conflict of interest.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: pmc-nxml

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-09-20T09:27:46.357103+00:00
unpaywall
last seen: 2026-05-21T05:10:58.409756+00:00
License: CC-BY-NC-4.0